asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

coto joins hands with Sirohi to offer a safe, empowering space for women artisans of Muzaffarnagar

by asianprimenews0746

National: With the aim of creating a sustainable impact and fostering sisterhood, coto, a social community platform for women, and Sirohi, an artisan-backed sustainable luxury brand join hands to elevate the lives of women artisans in Muzaffarnagar. This association will entail a series of on-ground workshops facilitated by coto community creators, experts and community leaders from NGOs and social impact organisations, addressing a variety of social barriers like health, mental health, parenting, and financial independence. SII has also partnered with the campaign to have an expert who will share valuable insights into the causes, symptoms, and prevention of Cervical cancer.

Both coto and Sirohi share a vision for social impact and empowerment and this initiative is a significant step towards realising the same. The initiative aims to create a safe space for marginalised women artisans between the age of 25-45 who find it difficult to discuss sensitive topics and regularly face societal taboos. Featuring a year-long workshop series, this initiative will contribute significantly towards educating these women on subjects like health and hygiene, mental wellbeing, parenting skills and ways to improve financial independence while encouraging open discussions on the same. As part of the initiative, through a strategic partnership with Zeelab, a medical camp will be conducted and free medical kits will be provided to the women artisans.
As an extension of this initiative, coto will introduce these women to its many digital communities on the platform to empower them towards ideas of self sufficiency and financial independence. The community will also help them in the process of self-development and boosting their individuality by honing their existing skill sets and encouraging them to break barriers one conversation at a time.
Speaking about this unique association, *Aparna Acharekar*, *Co-founder, coto* said, “Since its inception, coto has envisioned providing a safe and secure digital environment for women wherein they can discuss their concerns, opinions and ideas without any apprehensions. We are delighted to collaborate with Sirohi as it gives us a chance to make an impact at the grassroots level. Through this initiative, we aim to bring conversations about mental health, women’s hygiene, parenting and fundamentals of financial literacy offline and empower them to make informed decisions and choices. ”

Discussing the impact of the collaboration, Gauri Malik, Founder, Sirohi, said, “We believe this association will bring a much needed change, not only in the mindset but also bring out the true potential of women artisans that we work with. Through this collaboration, we aim to hold a variety of impactful conversations that are not only inspiring but also encourage them to have an individual standing in their immediate environment. This initiative will act as an extension of our already existing skill development and training programmes that focus on other social aspects of their lives.”

Through this initiative, coto and Sirohi aim to extend their support to women groups to raise their level of knowledge and understanding. The idea is to empower their core belief systems to break out of their domestic responsibilities and expectations, voicing their concerns, opinions and thoughts.

Here’s where you can download coto:
coto on App store: Android | Apple
coto’s Social media: Instagram | Twitter | LinkedIn | Facebook | YouTube
About coto: coto, which stands for ‘come together’, is a women-only social community app, based on the principles of Web3, that proffers expression, creation, and community enablement. It is an intimate and safe online space where women can discuss anything and everything without the fear of being judged or trolled. It provides synergy between content creation and community building, in which every user holds actual value and ownership of the content that they create. In a safe and secure community environment, the platform provides information and answers to all questions on topics such as PCOS, menstrual hygiene, wellness, diet and fitness, emotional wellness to beauty, fashion, travel and lots more. With its foundations on empowerment and sisterhood, coto is built on the promise of consent and continual ownership. coto boasts of 250,000+ user base on the platform with 5000+ thriving communities by women across genres have been built on coto.

About Sirohi: “Sirohi is a design-first, artisan-backed brand for sustainable home decor and lifestyle products, primarily working with artisan clusters and empowering artisans from 5 states across India.
We use technology as a medium to provide high-quality design training and direct market access to women artisans, so they can make quality-focused, well-designed handmade products, resulting in 40% higher wages compared to traditional artisans in India and reducing 70% migration from crafts to other professions.”

Sirohi’s Social media handle: Linkedin, Instagram, Facebook & Youtube

About Zeelab: Zeelab is a new age pharmacy that sells medicines, nutraceuticals, and aligned products at upto 90% lower cost to patients. Zeelab manages development and distribution of its products in-house and partners with leading manufacturers. It markets its own brands directly to consumers through 130 Company owned stores, 1400 franchise stores and processing 15000 orders monthly through web & app with over 100,000+ downloads.
website: www.zeelabpharmacy.com
Linkedin: https://in.linkedin.com/company/zeelab-pharmacy
Insta: https://www.instagram.com/zeelabpharmacy
Facebook: https://www.facebook.com/zeelabpharmacy.official/

Share

Related posts

Dior unveils an exceptional new ambassador: Sonam Kapoor

asianprimenews

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

POCO C71 Drops on Flipkart at ₹ 6499 with a Blockbuster Display & Power-Packed Features!

asianprimenews